Cel Sci Corporation (CVM)

[Phoenix2020]

70.92% Daily Short Volume but PPS up 2.67%!

70.92% of the daily volume has been shorted on Friday (as reported by FINRA) but the PPS went up 2.67%! The number of available shares for shorting is 90'000 and the borrow fee is 11.1%! The short volume has come down more than 1 million shares from 6.04 million to 4.97 million shares over the last month and it seems that the shorts are covering under the radar. The data has been published on ClinicalTrials and confirms that Multikine is a drug with a median extended life expectancy of almost 4 years and zero toxicity! Further, 5 patients had their tumours completely disappear and were CURED after 3 weeks of Multikine treatment and before surgery!! GLTAL! Tick tock, tick tock ...

And here are two quotes from Geert Kersten's latest interview with Global Market Bulletin TV in May:

"It's all about bringing the drug to market. The beautiful thing is this: we're very much de-risked. Right, the big risk in a biotech company is, you know what will the data show. Will the drug even work? Well, you see it very clearly — it's multi-years of life extension, right. Tumours going away. And no toxicities, no safety issues. So that's been de-risked — all you have to be thinking about is will this drug come to market and by which pathway."

"The Canadians gave us the path. The Canadians said, we understand that there's great benefit for these patients. We also see your study is different from anything we've seen before, so conditional is the best way to go. The European regulations, I mean I have them here, I'm not going to bother reading them to you, but you have to show that risk-benefit balance of the medicine is positive, that you can do follow-on studies, that it's an unmet medical need and that the medicine's immediate availability to patients is greater than the risk inherent in the fact that additional data is needed. It seems obvious to me that we fit all of those requirements too."